STOCK TITAN
  1. Home
  2. GNBT

Generex Biotechnology (GNBT) Stock Price, News & Analysis

GNBT
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
91 178 sessions, December 31, 2021 to October 27, 2022
Largest daily move
+1566.7% close of March 2, 2022

Company Description

GNBT has declined 99.0% so far this year. The last closing price was $0.0006.

This page collects what Stock Titan holds for GNBT, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
-
-
Last updated:
-99%
Performance this year
-
Market Cap
-
Shares outstanding

Generex Biotechnology (GNBT) closed at $0.0006 on October 27, 2022. So far this year, the price has lost 99.0%.

See what a $1,000 investment in GNBT would be worth today

GNBT Metrics & Rankings

Month to date
-14.3%
View ranking
YTD
-99.0%
View ranking

Price returns through October 27, 2022. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Latest News

View All
-99.57%

Generex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian Distribution Partner, Nexgen Medical, has gained approval for the use of Excellagen® Wound Conforming Matrix from The Malaysian Ministry of Health, its country’s equivalent to the U.S. FDA

fda approval
-99.57%

NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm

-99.57%

Generex Biotechnology Subsidiary NuGenHealth Contracts with Westside Medicine & Cardiology, Inc. to Provide Remote Patient Monitoring (RPM) Services

-99.57%

Generex Posts Recording of May 6 Shareholder Conference Call Highlighting its Ii-Key COVID Complete Vaccine™ and its Go-Forward Plans for Revenue Producing Assets

conferences covid-19
-99.57%

Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient Monitoring (RPM) Services

-99.57%

Generex Provides Clarification on Its Ii-Key COVID-19 Complete Vaccine China Partnership Agreement

partnership covid-19
-99.57%

Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at 9:00 AM

conferences
-99.57%

Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Agreement with Nexgen Medical for Distribution of Excellagen® Wound Conforming Matrix in Malaysia

-99.57%

Generex Provides Update on its Ii-Key COVID-19 Complete Vaccine Program: Advancing Global Development

covid-19
-99.57%

NuGenerex Immuno-Oncology Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission

fda approval

Generex Biotechnology has 10 recent news articles. Of the recent coverage, 0 articles coincided with positive price movement and 10 with negative movement. Key topics include fda approval, conferences, covid-19, partnership. View all GNBT news →

SEC Filings

View All

No SEC filings available for GNBT.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

Frequently Asked Questions

What is the current quoted price of Generex Biotechnology (GNBT)?

The current quoted price of Generex Biotechnology (GNBT) is $0.0006 as of October 27, 2022.